Related Experiment Video
Updated: Mar 30, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.4K
High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour
Olga Kondrashova1, Clare J Love1, Sebastian Lunke1
1Department of Pathology, University of Melbourne, Melbourne, VIC, Australia.
Plos One
|November 17, 2015
Summary
This study introduces MLPA-seq, a novel assay for accurate gene copy number determination in tumor samples. This high-throughput method reliably detects deletions, duplications, and amplifications, improving upon traditional techniques for cancer research.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Next-generation sequencing reliably detects point mutations but struggles with accurate copy number determination in fixed tumor tissues.
- Conventional Multiplex Ligation-dependent Probe Amplification (MLPA) is limited to approximately 50 targets due to probe size resolution.
- Accurate gene dosage measurement is crucial for understanding tumor development and guiding treatment strategies.
Purpose of the Study:
- To develop a scalable, high-throughput, and quantitative assay for precise copy number analysis in tumor DNA.
- To overcome the limitations of traditional MLPA by shifting from size-resolved to sequence-resolved detection.
- To validate the efficacy of the new assay in detecting copy number variations in various tumor sample types.
Main Methods:
- Developed MLPA-seq, a sequence-resolved quantitative assay for gene copy number analysis.
- Utilized minimal genomic DNA input (as little as 5ng), including from formalin-fixed paraffin-embedded (FFPE) samples.
- Applied MLPA-seq to detect copy number changes in key genes (BRCA1, BRCA2, ERBB2, CCNE1) in both snap-frozen and FFPE tumor tissues.
Main Results:
- MLPA-seq successfully detects deletions, duplications, and amplifications with high sensitivity and specificity.
- The assay demonstrated 100% sensitivity and >99.5% specificity for detecting copy number changes in BRCA1, BRCA2, ERBB2, and CCNE1.
- The method is effective even with limited amounts of DNA from challenging FFPE tumor samples.
Conclusions:
- MLPA-seq offers a scalable and high-throughput solution for accurate gene copy number determination in tumor samples.
- This novel assay overcomes the target number limitations of conventional MLPA, enabling comprehensive genomic analysis.
- MLPA-seq provides a reliable tool for detecting clinically relevant copy number alterations in both fresh and FFPE tumor tissues, advancing cancer diagnostics and research.
